Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

Inclusion Criteria:

• Documented informed consent of the participant and/or legally authorizedrepresentative

• Assent, when appropriate, will be obtained per institutional guidelines

• Agreement to allow the use of archival tissue from diagnostic tumor biopsies

• Age >= 18 years

• Eastern Cooperative Oncology Group (ECOG) 0 or 1

• Lung non-small cell carcinoma (NSCLC) patients with advanced, metastatic, orrecurrent disease, previously treated with a PD-1 or PD-L1 immune checkpointinhibitor, either as single agent or in combination with chemotherapy or otherimmunotherapy or experimental agents

• Radiographically demonstrable tumor progression treatment on or after therapy with aPD-1/PD-L1 immune checkpoint inhibitor

• Preserved organ function and recovery of prior drug related toxicities (exceptalopecia or grade 2 anemia) to grade 1 or better

• No cytotoxic chemotherapy or immunotherapy over the three weeks prior tolymphodepletion

• Histologically confirmed non-small cell lung cancer

• Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST)criteria 1.1

• Fully recovered from the acute toxic effects (except alopecia) to =< grade 1 toprior anti-cancer therapy

• Absolute neutrophil count (ANC) >= 1,500/mm^3

• Hemoglobin (Hgb) >= 8 g/dl

• Platelets >= 100,000/mm^3

• Total bilirubin =< 1.5 x upper limit of normal (ULN)

• Aspartate aminotransferase (AST) =< 1.5 x ULN

• Alanine aminotransferase (ALT) =< 1.5 x ULN

• Alkaline phosphatase (AP) =< 1.5 x ULN

• Creatinine clearance of >= 60 mL/min per 24-hour urine test or the Cockcroft-Gaultformula

• If not receiving anticoagulants: International normalized ratio (INR) OR prothrombin (PT) =< 1.5 x ULN

• If on anticoagulant therapy: PT must be within therapeutic range of intended use ofanticoagulants

• Seronegative for human immunodeficiency virus (HIV) antigen (Ag)/antibody (Ab)combo, hepatitis C virus (HCV), active hepatitis B virus (HBV) (surface antigennegative)

• If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed

• Women of childbearing potential (WOCBP): Negative urine or serum pregnancy test. Ifthe urine test is positive or cannot be confirmed as negative, a serum pregnancytest will be required

• Agreement by females and males of childbearing potential to use an effective methodof birth control or abstain from heterosexual activity for the course of the studythrough at least 06 months after the last dose of protocol therapy

• Childbearing potential defined as not being surgically sterilized (men andwomen) or have not been free from menses for > 1 year (women only)

Exclusion Criteria:

• Autologous stem cell transplant within 1 year prior to day 1 of protocol therapy

• Chemotherapy, radiation therapy, biological therapy, immunotherapy within 21 daysprior to day 1 of protocol therapy

• History of allergic reactions attributed to compounds of similar chemical orbiologic composition to study agent

• Active diarrhea

• Clinically significant uncontrolled illness

• Active infection requiring antibiotics

• Known history and/or positive serology for immunodeficiency virus (HIV) or hepatitisB or hepatitis C infection

• Diagnosis of Gilbert's disease

• Other active malignancy

• Females only: Pregnant or breastfeeding

• Severe (grade 3 or higher) immune related adverse events during prior PD-1 inhibitortreatment

• Any other condition that would, in the Investigator's judgment, contraindicate thepatient's participation in the clinical study due to safety concerns with clinicalstudy procedures

• Concomitant use of other investigational agents

• Patients with EGFR mutations or ALK translocations in their tumors, unless treatmentwith the indicated tyrosine kinase inhibitor has failed

• Active brain metastases. Previously treated brain metastasis must demonstratestability on subsequent magnetic resonance imaging (MRI) scans

• Prospective participants who, in the opinion of the investigator, may not be able tocomply with all study procedures (including compliance issues related tofeasibility/logistics)